&quot;GINEXMAL RCT: Induction of labour versus expectant management in gestational diabetes pregnancies&quot; by Maso, G1 et al.
STUDY PROTOCOL Open Access
“GINEXMAL RCT: Induction of labour versus
expectant management in gestational diabetes
pregnancies”
Gianpaolo Maso1*, Salvatore Alberico1, Uri Wiesenfeld1, Luca Ronfani1, Anna Erenbourg1, Eran Hadar2, Yariv Yogev2
, Moshe Hod2 and for The GINEXMAL Study Cooperative Research Group1
Abstract
Background: Gestational Diabetes (GDM) is one of the most common complications of pregnancies affecting
around 7% of women. This clinical condition is associated with an increased risk of developing fetal macrosomia
and is related to a higher incidence of caesarean section in comparison to the general population. Strong evidence
indicating the best management between induction of labour at term and expectant monitoring are missing.
Methods/Design: Pregnant women with singleton pregnancy in vertex presentation previously diagnosed with
gestational diabetes will be asked to participate in a multicenter open-label randomized controlled trial between
38+0 and 39+0 gestational weeks. Women will be recruited in the third trimester in the Outpatient clinic or in the
Day Assessment Unit according to local protocols. Women who opt to take part will be randomized according to
induction of labour or expectant management for spontaneous delivery. Patients allocated to the induction group
will be admitted to the obstetric ward and offered induction of labour via use of prostaglandins, Foley catheter or
oxytocin (depending on clinical conditions). Women assigned to the expectant arm will be sent to their domicile
where they will be followed up until delivery, through maternal and fetal wellbeing monitoring twice weekly. The
primary study outcome is the Caesarean section (C-section) rate, whilst secondary measurement4s are maternal
and neonatal outcomes. A total sample of 1760 women (880 each arm) will be recruited to identify a relative
difference between the two arms equal to 20% in favour of induction, with concerns to C-section rate. Data will be
collected until mothers and newborns discharge from the hospital. Analysis of the outcome measures will be
carried out by intention to treat.
Discussion: The present trial will provide evidence as to whether or not, in women affected by gestational
diabetes, induction of labour between 38+0 and 39+0 weeks is an effective management to ameliorate maternal
and neonatal outcomes. The primary objective is to determine whether caesarean section rate could be reduced
among women undergoing induction of labour, in comparison to patients allocated to expectant monitoring. The
secondary objective consists of the assessment and comparison of maternal and neonatal outcomes in the two
study arms.
Trial Registration: The study protocol has been registered in the ClinicalTrials.gov Protocol Registration System,
identification number NCT01058772.
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Background
GDM is one of the most common complications of
pregnancy and its incidence is estimated at 7% [1].
Among women affected by GDM, an increased rate of
C-section has been observed, mostly unjustified [2,3].
Recent studies identified a C-section rate among women
with this condition as high as 35% [4], and indicated a
probability of undertaking a C-section in this group
around 1.5 times the probability among non-GDM
women [5].
Furthermore, babies born from women with GDM are
significantly more exposed to perinatal risk, mostly
related to fetal macrosomia [6]. This clinical condition
is in fact associated to an increased risk of intrapartum
traumatic lesions and asphyxia [7]. The incidence of
macrosomia or birth weight above the 90th percentile is
more common among these women, in comparison to
the general population [8]. These newborns, because of
their peculiar intrauterine growth pattern, are charac-
terised by a trunk mass larger than the head and conse-
quently are more exposed to shoulder dystocia, bone
fractures and brachial plexus injury, possibly with per-
manent outcomes [9,10].
The American College of Obstetricians and Gynecolo-
gists recommends a caesarean section for women with
GDM and estimated fetal weight > 4500 g [11]. The
American Diabetes Association recommends that GDM
by itself is neither an indication for C-section nor for
induction of labour before 38 completed gestational
weeks [12]. Pregnancy prolongation beyond 38 weeks
increases the risk to develop fetal macrosomia, without
reducing C-section rate. As a result, delivery within the
38th week of pregnancy is advisable if there are not
other specific obstetric recommendations to determine
an alternative management [12].
The guidelines currently in use are mainly based on
retrospective studies and the experiences of single hos-
pitals in the context of maternal and perinatal outcomes.
As a consequence, there is ample possibility of variation
in the clinical management of these women (expectant,
induction or elective C-section) if determined by health
professionals’ individual preference [1]. To the best of
our knowledge, only a randomized clinical trial [13] has
been carried out and it has been included in the most
recent Cochrane review investigating this issue [6].
Results of this trial suggested that expectant manage-
ment after 38 weeks of pregnancy reduced Caesarean
delivery rate and also increased the prevalence of large
for gestational age newborns and shoulder dystocia [13].
Despite the importance of these results, this study was
flawed by several methodological limitations. The rando-
mization method and allocation concealment were not
reported [10] and the sample population included both
women with insulin-requiring gestational diabetes and
class B pre-gestational. In addition, few non-randomized
clinical trials [14,15] and small number of observational
studies [8,16-19] have been published on this issue, but
obvious methodological limitations interfered from
drawing any definitive conclusions.
Strong evidence, based on adequately designed pro-
spective studies and randomized controlled trials, in
favour or against the effectiveness and safeness of induc-
tion in women with GDM are missing [1,10]. In light of
this clinical dilemma, we propose a multicenter rando-
mized controlled trial comparing induction of labour at
38-39 gestational weeks to careful expectant monitoring.
Methods/Design
The proposed research regards a multicentre open label
randomized controlled trial in women with GDM
between 38+0 and 39+0 gestational weeks. The study
will be carried out by the GINEXMAL Study Coopera-
tive Research Group including 9 Teaching Hospitals, 5
in Italy and 4 abroad. The Institute for Maternal and
Child Health - IRCCS Burlo Garofolo (Italy) together
with The Helen Schneider’s Hospital for Women -
Rabin Medical Centre (Israel) will be the coordinating
centre of the research project.
A total sample of 1760 patients (N = 880 per interven-
tion group) will be recruited. The sample size has been
estimated to be sufficiently large to achieve significant
results with concerns to the main outcome of the study.
In particular, it will be able to demonstrate a difference
between the two arms ≥ 6% (31% of C-section in the
expectant group and 25% in the induction group; rela-
tive difference between the 2 groups equal to 20% in
favour of induction [13]), considering a error equal to
5% and 80% power.
Randomization will be centralized and coordinated by
the Epidemiology and Biostatistics Unit (IRCCS Burlo
Garofolo, Italy) using a computer-based method. The
randomization list will be blocked (using blocks with a
size of 10) and stratified by centre. The allocation con-
cealment will be guaranteed through the use of closed
opaque envelopes, consecutively numbered. In each
envelope a patient’s allocation group will be indicated,
based on randomization. The study will be an open
label trial because of the practical impossibility to blind
either health professionals or patients to the allocation
group.
Medical personnel directly involved in the manage-
ment of the patient, will open the first available envel-
ope and assign the patient to the corresponding
randomization group (experimental group: induction of
labour or control group: expectant management). The
recruitment phase of the study will last 2 years.
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Women older than 18 years of age with a singleton
pregnancy in vertex presentation diagnosed with GDM
in their current pregnancy will be eligible. Gestational
diabetes mellitus is defined as carbohydrate intolerance,
with onset or first recognition during pregnancy [20,21].
Diagnosis will be based upon abnormal 50 gr Glucose
Challenge Test (GCT) (> 140 mg/dl) followed by 2
abnormal indices in the Oral Glucose Tolerance Test
(OGTT) (according to Carpenter & Coustan Criteria).
Women with GCT > 200 mg/dl will undergo 100 gr
OGTT as well. If prior to the beginning of the study
initial HAPO study consensus is available [21], diagnosis
of GDM will be based on these criteria. Patients charac-
terised by the mentioned eligibility criteria (Table 1) will
be asked to take part in the study during a consultation
at the Outpatient clinic at approximately 35 weeks of
gestational age. At the consultation the patient will first
have the protocol explained verbally. In order to give
the individual an opportunity to consider the proposed
proceedings, they will be left with a paper copy of the
protocol for a short period of time. If the patient
expresses a desire to take part, she will then be referred
to the Day Assessment Unit between 38+0 and 39+0
weeks of gestational age.
If there are no other contraindications to deliver vag-
inally, patients will be enrolled between 38+0 and 39+0
weeks of gestational age (verified by last menstrual per-
iod (LMP) and confirmed by first trimester ultrasound).
In the case of a discrepancy, gestational age assessed by
ultrasound in the first trimester will be considered as
the true reference. Uncertain gestational age or any
major fetal anomaly will cause exclusion from the trial
(Table 1). Women diagnosed with pre-gestational dia-
betes or demonstrating a prior C-section in their obste-
trical history will be excluded. The identification of non-
reassuring fetal status assessed by cardiotocography
alone or as a formal part of a biophysical profile [22] or
the presence of maternal or fetal conditions complicat-
ing pregnancy (e.g. severe preeclampsia/HELLP Syn-
drome or severe fetal growth restriction) and requiring
immediate obstetrical intervention (prompt delivery or
prompt C-section) will lead to the patient’s exclusion.
After careful evaluation of inclusion and exclusion cri-
teria (Table 1), suitable patients will have been identi-
fied. On the day of enrolment, an ultrasound assessment
of fetal weight, as well as a Bishop score evaluation, will
be performed. Whenever the estimated fetal weight
exceeds 4000 gr, patients will be excluded from the trial
and offered a C-section. A Bishop score greater than 7
will automatically exclude the patient from the trial.
Furthermore, an attentive evaluation of possible contra-
indications to vaginal delivery and an assessment of fetal
wellbeing through a cardiotocographic trace will be car-
ried out at enrolment. The remaining inclusion/exclu-
sion criteria will be assessed through the evaluation of
the patient’s current and past obstetric records.
Eligible women will be provided a comprehensive
explanation of the project by the obstetrician on call, in
terms of study procedures and risks versus benefits
attached. Patients wishing to take part will be asked to
sign a written consent form before being allocated to
the randomization group.
Data about obstetric history will be collected through
consultation with the patient and evaluation of the
patient’s previous records and clinical reports. The out-
comes will be evaluated during delivery and until mater-
nal and neonatal discharge. Perinatal and maternal
deaths will be identified until discharge. Perinatal deaths
should include events up to 7 days after birth and most
newborns will be discharged earlier. Our assumption is
Table 1 Inclusion and Exclusion Criteria
Inclusion Criteria
Maternal age ≥ 18 years
Singleton pregnancy in vertex presentation
Gestational age between 38 and 39 weeks verified by LMP and confirmed by first trimester ultrasound
Women diagnosed with GDM in the present pregnancy




Suspected estimated foetal weight > 4000 g at enrolment
Any known contraindications to vaginal delivery
Uncertain gestational age
Non reassuring foetal wellbeing necessitating delivery
Maternal pregnancy-related disease necessitating delivery
Bishop score > 7 at enrolment
Known foetal anomaly
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that perinatal death would occur almost exclusively in
newborns manifesting complications during admission
and consequently this could be accurately estimated by
the time of discharge. At enrolment, patients assigned
to the induction group will be admitted to the obstetric
ward (Figure 1). Induction of labour will be performed
by using dinoprostone, 2 mg vaginally, or dinoprostone,
0.5 mg intracervically, in 6-8 hour intervals (up to 5
doses) or dinoprostone, 10 mg vaginal device. Once the
patient’s Bishop score exceeds 7 or regular contractions
are diagnosed, patients will be transferred to the delivery
ward for artificial rupture of membranes (ARM) or oxy-
tocin augmentation as indicated. Patients, in which cer-
vical ripening does not occur (Bishop score < 7) after 5
attempts with Prostaglandin E2 (PGE2), will be offered
either oxytocin or Foley catheter induction or C-section,
according to local protocols.
Patients enrolled in the conservative management arm
will be followed up twice weekly by Electronic Fetal
Heart Rate monitoring and Biophysical profile (Figure
1). Patients will be followed up until 41+0 gestational
weeks. Women, who will not deliver by this gestational
age, will be admitted for labour induction (see the pro-
tocol above). Induction of labour will be offered when
non-reassuring fetal status is suspected. All patients in
the conservative arm will undergo fetal weight ultra-
sound estimation prior to induction. Patients with esti-
mated fetal weight over 4000 gr will be offered a
caesarean section.
General information on recruited patients, outcomes
and randomization group will be indicated in an appro-
priate paper questionnaire in the first instance and then
reported on an electronic database accessible from
different study sites in the second instance. In each par-
ticipating centre, medical personnel will fill up the elec-
tronic form directly. Data will be kept anonymous and
will be analyzed by the Epidemiology and Biostatistics
Unit - IRCCS Burlo Garofolo, using STATA 9 statistical
package. Continuous variables will be reported as mean
and standard deviation, categorical variables as propor-
tions and percentages. The two groups will be compared
by their main characteristics to evaluate the efficacy of
the randomization process. To evaluate the main out-
come of the study, C-section incidence will be compared
between the two groups using the c2 test. Possible con-
founders such as: blood glucose control, obesity, partici-
pating centre policy etc. will be controlled through
multivariate analysis (logistic regression). To compare
secondary outcome variables between the two groups,
the ANOVA technique will be used for continuous vari-
ables and c2 test for categorical. Statistically significant
differences will be determined by a p-value inferior to
0.05. Although crossovers between the two allocation
groups could complicate data interpretation, it is impos-
sible to prevent them. However, data will be analysed by
intention-to-treat. Finally, a sensitivity analysis will be
carried out to confirm that results do not change signifi-
cantly despite the variety of populations included in the
study.
Data will be monitored by The Epidemiology and
Biostatistics Unit at The Institute for Maternal and
Child Health - IRCCS Burlo Garofolo. Serious adverse
events will be reported to an apposite committee. This
will consist of three senior obstetricians working at dif-
ferent recruiting centres who will independently verify
that the adverse outcome has occurred, through
Figure 1 Trial Flow chart.
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assessing the patient’s record. The Steering Committee
for this trial will comprise Dr Salvatore Alberico (as
chairman), Professor Moshe Hod and Professor Annun-
ziata Lapolla.
Ethical approval of the protocol was obtained by Burlo
Garofolo Ethical Committee (Coordinating Centre).
Approval at each participating centre is required before
starting the recruitment process and application for
approval at each local Ethical Committee will take place
in the next few months. The procedure will be explained
in detail to recruited patients, who will be provided an
information sheet and finally asked to sign a consent
form if willing to participate.
Discussion
The aim of the present study is to assess whether induc-
tion of labour at term would reduce C-section rate and
ameliorate maternal and neonatal outcomes when com-
pared to expectant management in pregnancies affected
by GDM.
The main outcome of the study was planned to be a
composite of main neonatal morbidity and mortality
outcomes possibly related to GDM. The choice of creat-
ing a composite outcome derived from the practical
impossibility of using shoulder dystocia alone as a single
outcome. The rarity of this event would have precluded
the possibility of carrying out the study, which would
require a very large number of women to obtain signifi-
cant results. The necessity of including very rare end-
points in a composite outcome in obstetrics research
has been recently highlighted [23]. The attempt to
include in a unique composite, the neonatal outcomes
of interest, has unfortunately failed. In fact this process
would have required combining very serious events,
such neonatal death or shoulder dystocia, to neonatal
hypoglycaemia or hyperbilirubinemia related to much
less serious consequences, and for this reason unfeasible.
Therefore the main outcome of the study was decided
to be the incidence of C-section among women under-
going induction of labour and those who will be
assigned to expectant management with attentive mater-
nal and fetal monitoring. This is a very relevant out-
come both for women’s health and for health service
organizations. Furthermore, C-section rate was the main
outcome of the only randomized controlled trial pre-
viously carried out on this topic [13].
Secondary outcomes of the study will be assessed at
time of delivery and/or during maternal and neonatal
admission until discharge. Outcomes evaluated at deliv-
ery are: gestational age, mode of delivery (spontaneous
or operative vaginal delivery, C-section), spontaneous or
instrumental third stage of labour, presence of perineal
tears or performance of an episiotomy, postpartum hae-
morrhage (defined as bleeding from the genital tract of
1000 ml or more in the first 24 hours following the
delivery of the baby) [20]. Furthermore, the occurrence
of shoulder dystocia, defined as a delivery that requires
additional obstetric manoeuvres to release the shoulders
after gentle downward traction has failed, will be evalu-
ated [24]. Shoulder dystocia occurs when either the
anterior or, less commonly, the posterior fetal shoulder
impacts on the maternal symphysis or sacral promon-
tory [24] and its diagnosis will be confirmed by an appo-
site committee for serious adverse events. Serious
adverse outcomes such as shoulder dystocia, fourth-
degree perineal tears and uterine rupture will be
reported to an independent data monitoring committee.
Finally, the eventual manoeuvres performed to disengage
the shoulder, newborn’s birth weight, Apgar score at 1’,
5’ and 10’ minutes, occurrence of arterial cord pH infer-
ior to 7.02 will be recorded and evaluated.
The remaining secondary outcomes will be assessed
until maternal and fetal discharge and are as follows:
need for blood transfusion (whose main determinant
should be the clinical picture and whose main therapeu-
tic goals are to maintain haemoglobin > 8 g/dl, platelet
count > 75 × 109/l, prothrombin < 1.5 × mean control,
activated prothrombin times < 1.5 × mean control, fibri-
nogen > 1.0 g/l, when used in the most appropriate
combination of intravenous clear fluids and blood pro-
ducts) [25], maternal or neonatal intensive care unit
admission, duration and diagnosis, neonatal birth
trauma (Erb’s palsy, bone fracture, intra-cerebral/intra-
ventricular haemorrhage, subdural hematoma), neonatal
respiratory distress/transient tachypnea, neonatal need
for respiratory support, neonatal hyperbilirubinemia,
polycythemia or hypoglycaemia and maternal and peri-
natal death.
Analysis of neonatal plasma glucose level collected 1-2
h after delivery is performed at the local laboratory and
results are provided to caregivers. Additional measure-
ments of plasma glucose may be performed for clinical
indications at the discretion of the attending physician,
if signs or symptoms suggest sustained or later develop-
ment of hypoglycemia. The need for other clinical
assessments, such as bilirubin levels or neonatal respira-
tory function, is determined by specific clinical indica-
tions. All data regarding the assessment of potential
neonatal morbidities are collected from the medical
records of the newborn.
GDM is a common complication of pregnancy and
could significantly affect fetal growth. Strong evidence
supporting a specific management on timing of delivery
of pregnant women with GDM is missing and there is
no consensus on this matter. Expectant monitoring
could determine an increase in macrosomic fetuses’ inci-
dence, leading to a higher C-section rate. Although
induction of labour could prevent fetal macrosomia and
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its consequences, its performance is thought to be possi-
bly related to an enhancement in C-section and instru-
mental vaginal delivery rates [26]. The aim of the
present trial is to provide evidence on the best manage-
ment of women at term, previously diagnosed with
GDM, in terms of maternal and neonatal outcomes.
The GINEXMAL protocol and copies of all forms may
be found on the following website: http://www.burlo.
trieste.it. Additional file 1 - Patient information sheet
and consent form, Additional file 2 - Patient recruitment
form.
Additional material
Additional file 1: Patient information sheet and Consent form.
Leaflet given to patients to explain what the project is about and form
need to be signed before randomization if they agree to participate.
Additional file 2: Patient recruitment form. Form to collect data about
maternal and neonatal outcome for each randomized patient.
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